Asthma
Asthma Exacerbation
search
Asthma Exacerbation
, Exacerbation of Asthma, Office-Based Management of Asthma Exacerbation
See Also
Pediatric Asthma Score
Asthma Management
Asthma Exacerbation Home Management
Emergency Management of Asthma Exacerbation
Asthma Inpatient Management
Status Asthmaticus
Asthma Exacerbation Severity Evaluation
Asthma-Related Death Risk Factors
Asthma Differential Diagnosis
Risk Factors
See
Asthma-Related Death Risk Factors
Acute
Viral
Upper Respiratory Infection
s (most common exacerbation trigger)
Chronic
Poor symptom control
Asthma Exacerbation in the last year
Poor
Medication Compliance
Incorrect use of asthma
Inhaler
Smoking
Chronic Sinusitis
Gastroesophageal Reflux
Definitions
Asthma Exacerbation
Deterioration in baseline symptoms (e.g.
Dyspnea
, chest tightness, cough,
Wheezing
) OR
Deterioration in objective markers (e.g.
Pulmonary Function Test
s,
Oxygen Saturation
)
Classification
Asthma Exacerbation Severity
See
Asthma Exacerbation Severity Evaluation
See
SMART Asthma Management Protocol
Mild Asthma Exacerbation
Dyspnea
on exertion (or
Tachypnea
in young children)
Peak Expiratory Flow
(PEF) >70% of predicted
Home management
Prompt relief with inhaled
Short-acting Beta Agonist
s
Moderate Asthma Exacerbation
Dyspnea
limits usual activity and patient may speak in phrases
Peak Expiratory Flow
(PEF) 40-69% of predicted
Tachypnea
may be present, but no accessory
Muscle
use
Oxygen Saturation
90 to 95%
Mild
Tachycardia
(100 to 120 bpm) may be present
Relief with frequent inhaled
Short-acting Beta Agonist
s
Office management
Add oral
Systemic Corticosteroid
s
Anticipate 1-2 days of symptoms after treatment onset
Severe Asthma Exacerbation
Dyspnea
at rest, limiting conversation
Patient may sit forward (e.g. tripoding)
Tachypnea
(>30 breaths/min),
Tachycardia
(pulse>120 bpm) or
Hypoxia
(
O2 Sat
<90%) may be present
Peak Expiratory Flow
(PEF) <40% of predicted
Only partial relief with inhaled
Short-acting Beta Agonist
s
Emergency department management
Hospitalization is likely
Add
Systemic Corticosteroid
s and ipratroprium
Anticipte >3 days of some symptoms
Life Threatening Asthma Exacerbation
Unable to speak, severe
Dyspnea
, with associated diaphoresis
Patient may be confused and with quiet chest, and inappropriately decreased work of breathing (
Peri-Arrest
)
Peak Expiratory Flow
(PEF) <25% of predicted
Minimal relief with inhaled
Short-acting Beta Agonist
s
Emergency department stabilization
Intensive Care
unit admission
Frequent or continuous
Albuterol Neb
s
Add
Systemic Corticosteroid
s and ipratroprium
ABC Management
Management
Gene
ral
See
Asthma Exacerbation Home Management
See
Emergency Management of Asthma Exacerbation
See
Asthma Inpatient Management
See
Status Asthmaticus
Management
Office-Based Management
See
Emergency Management of Asthma Exacerbation
Indications
Mild to moderate Asthma Exacerbation in age >= 6 years
Contraindications: Need for emergency department management (arrange urgent transfer, while performing stablization below)
Severe or life threatening Asthma Exacerbation
Oxygen Saturation
<90%
Failed acute office-based management as below
Protocol: Acute Office Management
Albuterol
MDI with spacer for 4 to 10 puffs, repeated every 20 minutes as needed for up to 1 hour
Consider adding
Ipratropium Bromide
(e.g. duonebs) in moderate exacerbations
Supplemental Oxygen
if
Oxygen Saturation
<90% (target
Oxygen Saturation
>93 to 94%)
Systemic Corticosteroid
(e.g.
Prednisolone
,
Prednisone
) 1-2 mg/kg up to 40-50 mg orally
Response will be delayed >6 hours
Disposition (based on 1 hour assessment)
Worsening or refractory status, or
Hypoxia
Transfer to emergency department
Discharge to home indications
Symptoms improving without the need for further
Albuterol
Oxygen Saturation
>93 to 94%
Peak Expiratory Flow
>60 to 80% of predicted or personal best
Adequate resources at home to continue Asthma Exacerbation management
Outpatient Management
Continue short-acting
Bronchodilator
as needed (or advance
SMART Asthma Management Protocol
)
Assess for proper
Inhaler
use with spacer
Review
Asthma Action Plan
Start or step-up controller medication
Continue oral
Corticosteroid
s for 3 to 5 days in children (5 to 7 days in adults)
Follow-up at 1 to 2 days in children (2 to 7 days in adults)
Assess for exacerbation improvement
Consider extension of
Systemic Corticosteroid
s if significant persistent, refractory symptoms
Consider short-term (1 to 2 weeks) or long-term (3 months) advancement of controller medications
Taper short-acting
Bronchodilator
as able (or
SMART Asthma Management Protocol
)
Review
Asthma Action Plan
(consider modifications and emphasize compliance)
Refer to
Asthma
and allergy specialist for >1 to 2 exacerbations per year
Prevention
See
Asthma-Related Death Risk Factors
Manage chronic modifiable predisposing conditions
School-based
Asthma
intervention programs
Cicutto (2013) J Sch Health 83(12): 876-84 [PubMed]
References
(2022) Global Strategy for
Asthma Management
and Prevention (GINA)
https://ginasthma.org/gina-reports/
(2007) Guidelines for the diagnosis and management of
Asthma
, NHLBI
Dabbs (2024) Am Fam Physician 109(1): 43-50 [PubMed]
Type your search phrase here